Vaccination and immunization aid in the prevention of diseases among adults and children. Vaccines are biological suspensions that contain an agent that resembles the disease-causing microorganisms and are often made from inactivated microbes, toxins, or surface proteins. The active agents present in the vaccine stimulate the body’s immune system to recognize the disease-causing agent as 'foreign substance' and develop antibodies against it. Vaccines are a preferable and highly recommended preventive measure against certain severe diseases; however, they have mild side effects such as fever, head ache, body pain.
The global adult vaccines market is estimated to be valued at US$ 16,790.11 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).
Figure 1. Global Adult Vaccines Market Share (%), by Vaccine, 2022
The increasing number of government initiatives to prevent certain diseases and epidemics are expected to drive the growth of the global adult vaccines market.
The increasing number of government initiatives to prevent certain diseases and epidemics are expected to drive the growth of the global adult vaccines market. According to the National Health Mission, India is committed to the goal of measles elimination and rubella control, and therefore, Measles Rubella (MR) vaccine was introduced in the country through a campaign mode in a phased manner in 2017. The Measles-Rubella (MR) campaign targets around 4.1 million children in the age group of 9 months to 15 years (covering ⅓ of the total population of the India) followed by 2 doses in routine immunization at 9-12 months and 16-24 months. Rubella component is now under routine immunization as MR vaccine.
Furthermore, Pneumococcal Conjugate Vaccine (PCV) was launched in May 2017 in India for reducing infant mortality and morbidity caused by pneumococcal pneumonia. It has since been introduced in Bihar, Himachal Pradesh, Madhya Pradesh, 19 districts of Uttar Pradesh, and 18 districts of Rajasthan in India. The National Cold Chain Training Centre (NCCTE), Pune and the National Cold Chain & Vaccine Management Resource Centre (NCCVMRC) - National Institute of Health and Family Welfare (NIHFW), New Delhi was established in 2019, to provide technical training to cold chain technicians in the repair & maintenance of cold chain equipment.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 16,790.11 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 7.1% | 2030 Value Projection: | US$ 29,025.87 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Adult Vaccines Market Share (%), by Region, 2022
Various countries are conducting national immunization programs to provide vaccination and promote awareness regarding the advantages of vaccination to fight fatal diseases are expected to drive the market growth.
Various countries are conducting national immunization programs are expected to drive the market growth over the forecast period. For instance, on February 17, 2022, the Centers for Disease Control and Prevention (CDC) published updated influenza vaccine schedules for adults in 2022. Furthermore, on January 12, 2022, the CDC's Advisory Committee on Immunization Practices (ACIP) meeting reviewed the following presentations: Seasonal Influenza Vaccines - H. Keipp Talbot, MD, MPH; Influenza Vaccines for Older Adults - Lisa Grohskopf Vaccine Policy Unit.
Moreover, in June 2022, according to the Australian Government Department of Health, the National Immunization Program (NIP) funds influenza vaccines for people who are most at risk for influenza virus infection. With the easing of international and domestic public health measures arising from the COVID-19 global pandemic, a revival of influenza is expected in 2022, the Australian community potentially more vulnerable to the virus in winters and took initiative to vaccinate the people in Australia.
Global Adult Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.
The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global adult vaccines market, owing to the increased research and development of vaccine to prevent coronavirus. For instance, on December 11, 2020, the Pfizer-BioNTech COVID-19 vaccine had been made available globally under Emergency Use Authorization (EUA) for individuals 16 years of age and older and was approved by the U.S. Food and Drug Administration as the first COVID-19 vaccine.
Global Adult Vaccines Market: Key Developments
In September 2021, the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices released updated recommendations on the use of influenza vaccines for the 2021-2022 influenza season. Flucelvax Quadrivalent, a cell culture-based inactivated influenza vaccine, got approved in October 2021 by the U.S. Food and Drug Administration for use in the U.S.
Global Adult Vaccines Market: Restraint
The major factors that hinder the growth of the global adult vaccines market include a large population not being vaccinated for certain diseases such as Tetanus, Diphtheria, and Pertussis. For instance, according to the National Health Interview Survey conducted in 2021 by the Centers of Disease Control & Prevention (CDC) 2021, 4 out of 5 people did not report for Tetanus, Diphtheria, and Pertussis (Tdap) vaccination in the U.S. The COVID-19 pandemic had affected adult vaccination coverage in 2020 because few adults might had visited Healthcare professional (HCP) where vaccinations are administered.
Key Players
Major players operating in the global adult vaccines market include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc.
Vaccines refer to the biological preparation that improves immunity to fight against a particular disease. Vaccines comprise suspensions formulated from weakened, killed or fragmented microorganisms, toxins or antibodies that are administered to a patient, with a primary intention to prevent a disease. Vaccines offer active immunity against specific harmful and disease causing agents by stimulating the immune system to attack the agent. Vaccines helps to protect individuals against serious and fatal diseases such as influenza and measles among others. Adult immunization that includes administration of licensed vaccine provided to patients aged 18 years and older, for medical indications. Vaccines are routinely administered to eliminate the infectious diseases among infants and children, however the Centers of Disease Control & Prevention (CDC), 2017, also recommends adults to periodically take up vaccination, referred to as adult vaccines. According to the CDC 2015, 30% of the patients from mission Healthy People program in the U.S. 2020 opted for shingles vaccine and were reported to be safe from preventable illness. Adult vaccines are given to age group to 18 year old and above.
Market Dynamics
Market players are increasingly focusing on creating vaccinations for illnesses having the highest risk of spreading like an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country. The disease affects chronically over 40 million people in 2018 in the country, as per India’s Universal Immunization Program. Moreover, Dynavax Technologies Corporation, Biopharmaceutical Company received the United States Food and Drug Administration (U.S.FDA) approval in 2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients